TrianglePUBLICATIONS · 35489363
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Oncol
- Publication date
- 2022 Jun
- First author
- Motzer R
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Motzer R
- type
- Author
- name
- Porta C
- type
- Author
- name
- Alekseev B
- type
- Author
- name
- Rha SY
- type
- Author
- name
- Choueiri TK
- type
- Author
- name
- Mendez-Vidal MJ
- type
- Author
- name
- Hong SH
- type
- Author
- name
- Kapoor A
- type
- Author
- name
- Goh JC
- type
- Author
- name
- Eto M
- type
- Author
- name
- Bennett L
- type
- Author
- name
- Wang J
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Motzer R
- type
- Author
- name
- Porta C
- type
- Author
- name
- Alekseev B
- type
- Author
- name
- Rha SY
- type
- Author
- name
- Choueiri TK
- type
- Author
- name
- Mendez-Vidal MJ
- type
- Author
- name
- Hong SH
- type
- Author
- name
- Kapoor A
- type
- Author
- name
- Goh JC
- type
- Author
- name
- Eto M
- type
- Author
- name
- Bennett L
- type
- Author
- name
- Wang J
- type
- Author
- bibliography ids
- nci-bib-b85fb9b7245940459d649d56
- book metadata
- content sha256
- d061735f365f17d93ebecf884ed893c65ff7990e0164e1b08d19f4e44453cc9f
- document type
- citation
- dois
- 10.1016/S1470-2045(22)00212-1
- electronic publication date
- display
- 2022 Apr 27
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:35489363
- immutable id
- pubmed:35489363@d061735f365f17d93ebecf884ed893c65ff7990e0164e1b08d19f4e44453cc9f
- journal
- abbreviation
- Lancet Oncol
- issn electronic
- 1474-5488
- issn print
- 1470-2045
- issue
- 6
- name
- The Lancet. Oncology
- nlm unique id
- 100957246
- pages
- 768-780
- volume
- 23
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 35489363
- provenance
- batch id
- 9d150d55960e0c12aada
- provider
- NCBI PubMed ESummary
- record sha256
- c117177ec399f293751acbcfbdba65d39bb102c8a2988f3198a40b4fcb9ab62b
- response sha256
- 2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
- retrieved at
- 2026-09-09T23:48:09.820498+00:00
- publication date
- display
- 2022 Jun
- precision
- month
- year
- 2022
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Preserved source evidence · Not medical advice